Tags

Type your tag names separated by a space and hit enter

Relapses after a single dose of rifampin in skin-smear negative multibacillary patients after dapsone monotherapy.
Int J Lepr Other Mycobact Dis. 1994 Jun; 62(2):209-14.IJ

Abstract

Between 1982 and 1985, a single 1500 mg dose of rifampin (RMP) was given to 136 multibacillary leprosy patients who had become clinically inactive and skin-smear negative after various durations of dapsone monotherapy, and then antileprosy chemotherapy was totally stopped. By the end of June 1992, 15 relapses were detected among these patients. The overall relapse rate was 11%; the relapse rate per 100 patient-years was 2.1%, which was the highest among those published to date; the cumulative risk of relapse at year 7 of follow up was 8.8%. All of these figures indicate that the relapse rate among this group was at least the same as in other studies where patients received dapsone monotherapy only. Therefore, the administration of a single large dose of RMP could neither prevent relapse nor reduce its rate among multibacillary patients who had already become clinically and skin-smear negative after dapsone monotherapy.

Authors+Show Affiliations

Institut Marchoux, Bamako, Mali.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8046259

Citation

Jamet, P, et al. "Relapses After a Single Dose of Rifampin in Skin-smear Negative Multibacillary Patients After Dapsone Monotherapy." International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, vol. 62, no. 2, 1994, pp. 209-14.
Jamet P, Blanc L, Fayne OC, et al. Relapses after a single dose of rifampin in skin-smear negative multibacillary patients after dapsone monotherapy. Int J Lepr Other Mycobact Dis. 1994;62(2):209-14.
Jamet, P., Blanc, L., Fayne, O. C., Traore, I., & Bobin, P. (1994). Relapses after a single dose of rifampin in skin-smear negative multibacillary patients after dapsone monotherapy. International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 62(2), 209-14.
Jamet P, et al. Relapses After a Single Dose of Rifampin in Skin-smear Negative Multibacillary Patients After Dapsone Monotherapy. Int J Lepr Other Mycobact Dis. 1994;62(2):209-14. PubMed PMID: 8046259.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Relapses after a single dose of rifampin in skin-smear negative multibacillary patients after dapsone monotherapy. AU - Jamet,P, AU - Blanc,L, AU - Fayne,O C, AU - Traore,I, AU - Bobin,P, PY - 1994/6/1/pubmed PY - 1994/6/1/medline PY - 1994/6/1/entrez SP - 209 EP - 14 JF - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association JO - Int J Lepr Other Mycobact Dis VL - 62 IS - 2 N2 - Between 1982 and 1985, a single 1500 mg dose of rifampin (RMP) was given to 136 multibacillary leprosy patients who had become clinically inactive and skin-smear negative after various durations of dapsone monotherapy, and then antileprosy chemotherapy was totally stopped. By the end of June 1992, 15 relapses were detected among these patients. The overall relapse rate was 11%; the relapse rate per 100 patient-years was 2.1%, which was the highest among those published to date; the cumulative risk of relapse at year 7 of follow up was 8.8%. All of these figures indicate that the relapse rate among this group was at least the same as in other studies where patients received dapsone monotherapy only. Therefore, the administration of a single large dose of RMP could neither prevent relapse nor reduce its rate among multibacillary patients who had already become clinically and skin-smear negative after dapsone monotherapy. SN - 0148-916X UR - https://www.unboundmedicine.com/medline/citation/8046259/Relapses_after_a_single_dose_of_rifampin_in_skin_smear_negative_multibacillary_patients_after_dapsone_monotherapy_ DB - PRIME DP - Unbound Medicine ER -